Shots:

• The P-III (INTRIGUE) evaluates the efficacy & safety of ripretinib vs sunitinib in patients with advanced GIST prior treated with imatinib at 122 active sites across 22 countries
• The study did not meet its 1EPs of superiority in PFS. In patients with a KIT exon 11 primary mutation & in AP population, m-PFS (8.3mos. vs 7.0mos.) & (8.0mos. vs 8.3mos.), ORR (23.9% vs 14.6%) & (21.7% vs 17.6%), was well tolerated, patients experienced grade 3-4 TEAEs (41.3% vs 65.6%)
• Qinlock is a switch-control TK inhibitor that inhibits KIT &  PDGFRA mutated kinases & has been approved in the US for advanced GIST. The therapy is also approved as 4L treatment of GIST in Australia, Canada & 6 other countries

Ref: Businesswire | Image: Deciphera